Can NT-pro BNP Levels Predict Prognosis of Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease in the Intensive Care Unit?

Background: The prognostic value of amino terminal pro-brainnatriuretic peptide levels in patients with acute exacerbation ofchronic obstructive pulmonary disease has not been fully established.Aims: To investigate the predictive value of amino terminal pro-brainnatriuretic peptide levels in terms of mortality, need for noninvasivemechanical ventilation, invasive mechanical ventilation, and weaningsuccess.Study Design: Cohort study.Methods: Patients who were admitted to intensive care unit betweenDecember 2015 and December 2016 due to acute exacerbation ofchronic obstructive pulmonary disease were included in the study.Demographic data, noninvasive mechanical ventilation application,need for invasive mechanical ventilation, amino terminal pro-brainnatriuretic peptide level, duration of mechanical ventilation, intensivecare unit and hospital stay, weaning success, and mortality rates wererecorded.Results: A total of 110 patients (75 males) were included in the study.The mean age of the participants was 69 (61-76) years, and the meanAcute Physiology and Chronic Health Evaluation II score was 19 (15-23). The mean amino terminal pro-brain natriuretic peptide level wasfound to be lower in cases with noninvasive mechanical ventilationsuccess than those with noninvasive mechanical ventilation failure(p=0.053). In addition, the mean amino terminal pro-brain natriureticpeptide level was significantly higher (4740 pg/mL vs. 3004 pg/mL,p=0.001) in patients who needed invasive mechanical ventilationsupport than in patients who did not. The mortality rate wassignificantly higher in patients who had an increasing trend of aminoterminal pro-brain natriuretic peptide levels during hospitalizationthan in patients who had decreasing levels (59% vs. 23%, p=0.015).Based on the receiver operating characteristic analysis, the increasingtrend of amino terminal pro-brain natriuretic peptide levels duringintensive care unit stay predicted mortality with area under curveof 0.84 (p

PDF

___

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Diseases (GOLD) 2017.
2. Pan W, Yu J, Zhang L, Yang H, Yuan Y. Predictors of in-hospital mortality in patients with acute exacerbation of COPD requiring ventilation: a retrospective study. Int J Clin Exp Med 2016;9:22093-22101.
3. Marcun R, Sustic A, Brguljan PM, Kadivec S, Farkas J, Kosnik M, et al. Cardiac biomarkers predict outcome after hospitalisation for an acute exacerbation of chronic obstructive pulmonary disease. Int J Cardiol 2012;161:156-9.
4. Chang CL, Robinson SC, Mills GD, Sullivan GD, Karalus NC, McLachlan JD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011;66:764-8.
5. Pavasini R, Tavazzi G, Biscaglia S, Guerra F, Pecoraro A, Zaraket F, et al. Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis. Chron Respir Dis 2017;14:117-26.
6. Bar SL, Swiggum E, Straatman L, Ignaszewski A. Nonheart failure-associated elevation of amino terminal pro-brain natriuretic peptide in the setting of sepsis. Can J Cardiol 2006;22:263-6.
7. Hawkins NM, Khosla A, Virani SA, McMurray JJ, FitzGerald JM. B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. BMC Pulm Med 2017;17:11.
8. Boles JM, Bion J, Connors A, Herridge M, Marsh M, Melot C, et al. Weaning from mechanical ventilation. Eur Respir J 2007;29:1033-56.
9. Niewoehner DE, Lokhnygina Y, Rice K, Kuschner WG, Sharafkhaneh A, Sarosi GA, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007;131:20-8.
10. Garcia-Aymerich J, Monso E, Marrades RM, Escarrabill J, Félez MA, Sunyer J, et al. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study. Am J Respir Crit Care Med 2001;164:1002-7.
11. Inoue Y, Kawayama T, Iwanaga T, Aizawa H. High Plasma Brain Natriuretic Peptide Levels in Stable COPD without Pulmonary Hypertension or Cor Pulmonale. Intern Med 2009;48:503-12.
12. Budweiser S, Luchner A, Jörres RA, Heinemann F, Hitzl AP, Schmidbauer K, et al. NT-pro BNP in chronic hypercapnic respiratory failure: a marker of disease severity, treatment effect and prognosis. Respir Med 2007;101:2003-10.
13. Stolz D, Breidthardt T, Christ-Crain M, Bingisser R, Miedinger D, Leuppi J, et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008;133:1088-94.
14. Nishimura K, Nishimura T, Onishi K, Oga T, Hasegawa Y, Jones PW. Changes in plasma levels of B-type natriuretic peptide with acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014;9:155-62.
15. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-9.
16. Adrish M, Nannaka VB, Cano EJ, Bajantri B, Diaz-Fuentes G. Significance of NTpro BNP in acute exacerbation of COPD patients without underlying left ventricular dysfunction. Int J Chron Obstruct Pulmon Dis 2017;12:1183-9.
17. Vassaux C, Torre-Bouscoulet L, Zeineldine S, Cortopassi F, Paz-Díaz H, Celli BR, et al. Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. Eur Respir J 2008;32:1275-82.
18. Mallawany HE, Mahmoud MI, Morsi TS, El- Skiekh RM. Role of N-terminal pro B-type natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis 2014;63:57-65.
19. Lari S, Attaran D, Vakilian F, Kamandi M, Disfani HF. Early Effectiveness of Noninvasive Positive Pressure Ventilation on Right Ventricular Function in Chronic Obstructive Pulmonary Disease Subjects with Acute Hyperapnic Respiratory Failure. J Cardio Thorac Med 2017;5:558-63.
20. Shah KB, Nolan MM, Rao K, Wang DJ, Christenson RH, Shanholtz CB, et al. The Characteristics and Prognostic Importance of NT-pro BNP Concentrations in Critically ill Patients. Am J Med 2007;120:1071-7.
21. Brueckmann M, Huhle G, Lang S, Haase KK, Bertsch T, Weiss T, et al. Prognostic Value of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Patients With Severe Sepsis. Circulation 2005;112:527-34.
22. Ruttem FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, et al. Unrecognised heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005;26:1887-94.
23. Porhomayon J, Papadakos P, Nader ND. Failed Weaning from Mechanical Ventilation and Cardiac Dysfunction. Crit Care Res Pract 2012;2012:173527.
24. Tsai SH, Lin YY, Chu SJ, Hsu CW, Cheng SM. Interpretation and Use of Natriuretic Peptides in Non - Congestive Heart Failure Settings. Yonsei Med J 2010;51:151-63.
25. Hoiseth AD, Omland T, Hagve TA, Brekke PH, Soyseth V. NT-pro BNP independently predicts long term mortality after acute exacerbation of COPD - a prospective cohort study. Respir Res 2012;13:97.